SEC Form SC 13G/A filed by BridgeBio Pharma Inc. (Amendment)
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $49.00 | Outperform | Wolfe Research |
| 3/31/2025 | $50.00 | Buy | Redburn Atlantic |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/3/2024 | Perform | Oppenheimer | |
| 9/4/2024 | $46.00 | Overweight | Piper Sandler |
| 3/21/2024 | $45.00 | Outperform | Raymond James |
| 1/31/2024 | $37.00 | Market Perform | BMO Capital Markets |
| 12/8/2023 | $58.00 | Overweight | Wells Fargo |
Wolfe Research initiated coverage of BridgeBio Pharma with a rating of Outperform and set a new price target of $49.00
Redburn Atlantic initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $50.00
Scotiabank initiated coverage of BridgeBio Pharma with a rating of Sector Outperform
Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity
SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
BridgeBio has received a $300 million upfront payment, strengthening the Company's balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio's European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to the investors subject to an initial cap of 1.45xIn the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients: In as few as 3 months, the time to first event (ACM or CVH) durably separated relative to placeboA 42% reduction in composite ACM and recurrent CVH events relative to placebo
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKR
- Data show that BBO-10203 covalently and specifically binds to the RAS-binding domain of PI3Kα, breaking its interaction with H-, N-, and KRAS and preventing them from activating PI3Kα - In preclinical models, BBO-10203 treatment led to significant tumor growth inhibition across multiple tumor types, and demonstrated enhanced efficacy when combined with other anti-tumor agents, without inducing hyperglycemia - BBO-10203 is currently being evaluated in a Phase 1 study in patients with HR+/HER2- or HER2+ BRCA, KRAS mutant colorectal cancer (CRC), and KRAS mutant non-small cell lung cancer (NSCLC) TheRas, Inc. d/b/a BBOT (the "Company"), a clinical-stage biopharmaceutical company focuse
4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci
PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be a
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR stabilizer (≥90%) was approved by the FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients on November 22, 2024 - Acoramidis was approved as BEYONTTRA™ in the EU on February 10, 2025, achieving a $75 million milestone payment and ongoing royalties in a tiered structure beginning in the low-thirties percent on sales in the EU - Acoramidis demonstrated a 59% hazard reduction on the composite endpoint of all-cause mortality and first
PALO ALTO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, on February 20, 2025. As part of the announcement, the Company will also share updates on Attruby's commercialization progress and its late-stage clinical pipeline. The Company will begin hosting earnings calls with the Q1 earnings release, expected in late April or early May, as outlined in its JPM presentation. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new ty